Premium
Effect of PMX‐DHP for sepsis due to ESBL‐producing E . coli in an extremely low‐birthweight infant
Author(s) -
Nishizaki Naoto,
Nakagawa Mayu,
Hara Satoshi,
Oda Hisayuki,
Kantake Masato,
Obinata Kaoru,
Uehara Yuki,
Hiramatsu Keiichi,
Shimizu Toshiaki
Publication year - 2016
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12825
Subject(s) - medicine , sepsis , polymyxin b , meropenem , polymyxin , antibiotics , hemoperfusion , low birth weight , escherichia coli , cefotaxime , ceftazidime , pediatrics , intensive care medicine , microbiology and biotechnology , pseudomonas aeruginosa , bacteria , antibiotic resistance , pregnancy , hemodialysis , biochemistry , genetics , gene , biology , chemistry
We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)‐type extended‐spectrum β ‐lactamase‐producing Escherichia coli (ESBL E . coli ) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B‐immobilized fibers with only 8 mL of priming volume. The patient survived without any short‐term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL‐producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low‐birthweight infant.